...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Clinical Medicine >Safety of Abatacept in Italian Patients with Rheumatoid Arthritis and Interstitial Lung Disease: A Multicenter Retrospective Study
【24h】

Safety of Abatacept in Italian Patients with Rheumatoid Arthritis and Interstitial Lung Disease: A Multicenter Retrospective Study

机译：意大利类风湿性关节炎和间质肺病患者ABATACEPT的安全性：多中心回顾性研究

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Treatment of rheumatoid arthritis (RA)-related interstitial lung disease (ILD) is challenging, and many conventional and biologic disease-modifying anti-rheumatic drugs (DMARDs) have been associated with ILD development or progression. The aim of this multicentric retrospective study was to analyze the evolution of ILD in Italian RA-ILD patients treated with abatacept (ABA). Methods: All RA-ILD patients treated with ABA for at least six months were retrospectively evaluated. Serology, previous and concurrent therapies, chest high-resolution computer tomography (HRCT), forced vital capacity (FVC), and lung diffusion of carbon monoxide (CO, DLCO) were collected. Results: Forty-four patients were included; HRCT, FVC, and DLCO were analyzed at baseline, at one year, and at the end of follow-up. A remission or a low disease activity of RA was reached in 41/44 patients. Overall, FVC and DLCO remained stable or increased in 86.1% and 91.7% of patients, respectively, while HRCT was stable or improved in 81.4% of them. Previous and concurrent treatments, in particular, methotrexate, serology, age, sex, joint and lung disease duration were not associated with the outcome at univariate analysis. Conclusion: The management of RA-ILD patients remains a critical unmet medical need. Waiting for prospective controlled studies, ABA has shown a good safety profile in our cohort of Italian RA-ILD patients.
机译：背景：类风湿性关节炎（RA） - 相关的间质肺病（ILD）是挑战性的，并且许多常规和生物疾病改性抗风湿药物（DMARDs）与ILD开发或进展相关。这种多中心回顾性研究的目的是分析意大利RA-ILD患者的ILD的演变（ABA）。方法：回顾性评价ABA至少六个月的所有RA-ILD患者。收集血清学，先前和并发疗法，胸高分辨率电脑断层扫描（HRCT），强制生命能力（FVC）和肺部扩散一氧化碳（CO，DLCO）。结果：包括四十四名患者;在基线，一年和随访结束时分析了HRCT，FVC和DLCO。在41/44名患者中达到了RA的缓解或低疾病活性。总体而言，FVC和DLCO分别保持稳定或增加86.1％和91.7％，而HRCT稳定或提高81.4％。以前和并发治疗，特别是甲氨蝶呤，血清学，年龄，性别，关节和肺病持续时间与单变量分析的结果无关。结论：RA-ILD患者的管理仍然是批判性未满足的药物需求。等待前瞻性对照研究，ABA在我们的意大利RA-ILD患者的队列中表现出良好的安全性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号